Dose responsive effects of subcutaneous pentosan polysulfate injection in mucopolysaccharidosis type VI rats and comparison to oral treatment.
BACKGROUND:We previously demonstrated the benefits of daily, oral pentosan polysulfate (PPS) treatment in a rat model of mucopolysaccharidosis (MPS) type VI. Herein we compare these effects to once weekly, subcutaneous (s.c.) injection. The bioavailability of injected PPS is greater than oral, sugge...
Main Authors: | Michael Frohbergh, Yi Ge, Fanli Meng, Nesrin Karabul, Alexander Solyom, Alon Lai, James Iatridis, Edward H Schuchman, Calogera M Simonaro |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4071040?pdf=render |
Similar Items
-
Pentosan Polysulfate: Oral Versus Subcutaneous Injection in Mucopolysaccharidosis Type I Dogs.
by: Calogera M Simonaro, et al.
Published: (2016-01-01) -
Pentosan polysulfate: a novel therapy for the mucopolysaccharidoses.
by: Edward H Schuchman, et al.
Published: (2013-01-01) -
Efficacy of pentosan polysulfate in in vitro models of lysosomal storage disorders: Fabry and Gaucher Disease.
by: Andrea N Crivaro, et al.
Published: (2019-01-01) -
Growth Plate Pathology in the Mucopolysaccharidosis Type VI Rat Model—An Experimental and Computational Approach
by: Johana M. Guevara-Morales, et al.
Published: (2020-05-01) -
Anti-TNF-alpha therapy enhances the effects of enzyme replacement therapy in rats with mucopolysaccharidosis type VI.
by: Efrat Eliyahu, et al.
Published: (2011-01-01)